At the molecular level, knockdown of Mettl3 and/or Mettl14 resulted in the upregulation of several oncogenes, including the genes encoding ADAM metallopeptidase domain 19 (ADAM19), EPH receptor A3 (EPHA3), and Kruppel-like factor 4 (KLF4), and downregulation of tumor suppressors such as genes encoding cyclin dependent kinase inhibitor 2A (CDKN2A), breast cancer 2, early onset (BRCA2), and tumor protein (TP53l11). The gene discussed is CDKN2A; the disease is breast cancer.